Recursion Pharmaceuticals is at the forefront of AI-driven drug discovery!

 Recursion Pharmaceuticals has caught the attention of major pharmaceutical companies due to its innovative approach to drug discovery. More recently, nVidia bought $70 Million of shares in $RXRX

Here’s why it’s worth knowing about:

1. AI-Driven Drug Discovery:

   Recursion collaborates with major biopharma companies to reduce research and development (R&D) costs and timelines. It employs AI-enabled methods to identify promising biological targets and molecules. By using digital chemistry and machine learning, Recursion calculates potential drug development targets efficiently.

2. Massive Data Repository:

   Recursion maintains an extensive database with over 3.1 trillion relationships between chemical and biological components. This data helps identify potential drug targets and streamline the drug discovery process.

3. Recent Acquisitions:

   Recursion recently acquired AI-related biotechs, Cyclica and Valence, which will enhance its drug discovery capabilities. These acquisitions aim to make Recursion even more effective at identifying drug targets and collaborating with pharmaceutical companies1.

4. Existing Collaborations:

    As we pointed out, powerful players like Roche and Bayer are already among Recursion’s patrons. Collaborating with Recursion allows these companies to leverage AI-driven approaches for drug discovery2.

5. Rare Disease Pipeline:

   Recursion also has its own development pipeline, including three programs in phase 2 clinical trials for rare diseases. For example, one program targets neurofibromatosis type 2, a condition affecting only 33,000 people worldwide. These pipeline projects could significantly boost Recursion’s revenue in the long term

6. Recursion Pharmaceuticals (RXRX on the Nasdaq)
7. offers a unique blend of AI-driven drug discovery, a vast data repository, and promising collaborations, making it an attractive partner for big pharmaceutical companies

Recursion Pharmaceuticals collaborates with NVIDIA to accelerate drug discovery using AI technology. Their newest supercomputer, BioHive-2, powered by 504 NVIDIA H100 Tensor Core GPUs, delivers 2 exaflops of AI performance—nearly 5x faster than their previous system.

Latest news:

Recursion Pharmaceuticals, Inc. - Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

Recursion ($RXRX)

Has developed an impressive artificial intelligence system called BioHive-2, which is powered by NVIDIA AI.  

 This supercomputer is specifically designed to accelerate drug discovery in the field of biology.

 

Let me share some details about it:

1. BioHive-2: Recursion’s BioHive-2 is the largest system in the pharmaceutical industry. It’s located at Recursion’s headquarters in Salt Lake City.

   This supercomputer ranks No. 35 on the latest TOP500 list of the world’s fastest supercomputers. 

2. It’s a significant improvement over its predecessor, BioHive-1, and delivers an impressive 2 exaflops of AI performance1.

3. AI in Drug Discovery: Recursion uses AI models on BioHive-2 to accelerate drug discovery. The field of biology is incredibly complex, and finding new drug candidates often involves years of wet-lab experiments.

   Recursion’s scientists can now run over 2 million experiments per week! 

4. With AI assistance, they can focus on the most promising areas, significantly reducing the need for extensive wet lab work. The goal is to achieve 80% of the value with only 40% of the experiments, thanks to AI-guided decision-making.

5. Massive Biological Dataset: Recursion collaborates with biopharma companies like Bayer AG, Roche, and Genentech. Over time, they’ve built a 50-petabyte database containing biological, chemical, and patient data. 

6. This vast dataset fuels powerful AI models that accelerate drug discovery. In fact, Recursion believes it’s one of the largest biological datasets globally, intentionally spanning both biology and chemistry.

7. Phenom Models: Using BioHive-1, Recursion developed a family of foundation models called Phenom. These models transform microscopic cellular images into meaningful representations for understanding underlying biology. 

8. Phenom-Beta, a member of this family, is now available as a cloud API and the first third-party model on NVIDIA BioNeMo, a generative AI platform for drug discovery1.

In summary, Recursion’s AI-driven approach is revolutionizing drug discovery by leveraging massive datasets, powerful AI models, and BioHive-2’s computational prowess. 

Their work has the potential to transform our understanding of biology and improve patients’ lives through better drug treatments

Disclosure: we are long $RXRX

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases